Extracellular Vesicle Targeting via Chemical Derivative Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for targeting extracellular vesicles (EVs) are time-consuming and require genetic modification of cells to express specific ligands, limiting their tropism and efficiency in therapeutic applications.
Innovation Solution
Engineering eukaryotic cells, particularly mammalian cells, to express transmembrane proteins with high affinity for chemical derivatives not naturally expressed by the cells, allowing the use of bifunctional molecules to bind ligands to EVs for targeted delivery, and optionally grafting these ligands onto the EVs for enhanced specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If genetic modification of cells is performed to express specific ligands for targeting EVs, then targeting specificity is improved, but development time and complexity increase
Solution Approach 1:
The patent applies preliminary action by pre-engineering transmembrane proteins with high affinity for chemical derivatives in the producer cells. This preliminary modification allows the EVs to be pre-equipped with targeting capabilities before isolation, enabling direct binding to ligands without requiring time-consuming genetic modification of target cells. The chemical derivative-conjugated ligands can then directly bind to these pre-engineered proteins on EV surfaces.
Solution Approach 2:
The patent uses chemical derivatives as intermediaries to bridge the gap between EVs and target cells. Instead of directly genetically modifying cells to express ligands, the invention introduces chemical derivative molecules that can conjugate to ligands and bind to the engineered transmembrane proteins on EVs. This intermediary approach simplifies the targeting process and reduces development complexity.
2Manufacturing precision
If genetic modification of cells is performed to express specific ligands for targeting EVs, then targeting specificity is improved, but process complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-engineering transmembrane proteins with high affinity for chemical derivatives in the producer cells. This preliminary modification allows the EVs to be pre-equipped with targeting capabilities before isolation, enabling direct binding to ligands without requiring time-consuming genetic modification of target cells. The chemical derivative-conjugated ligands can then directly bind to these pre-engineered proteins on EV surfaces.
Solution Approach 2:
The patent changes the parameter of protein affinity by engineering transmembrane proteins to have high affinity for specific chemical derivatives. This parameter change allows the use of simple chemical conjugation methods instead of complex genetic modification procedures. The high affinity ensures specific binding while the chemical nature of the interaction simplifies the overall process compared to genetic approaches.
3Manufacturing precision
If chemical derivatives with high affinity are used for binding ligands to EVs, then on-target delivery is improved, but off-target effects may increase
Solution Approach 1:
The patent applies local quality by engineering specific transmembrane proteins at specific locations on the EV surface to have high affinity for chemical derivatives. This localized engineering ensures that the targeting function is concentrated at specific sites on the EV membrane, allowing precise control over where and how ligands bind. The local modification approach enables high on-target delivery while maintaining control over binding specificity to minimize off-target effects.
Solution Approach 2:
The patent employs feedback mechanisms by selecting chemical derivatives and ligands with specific affinity characteristics that allow for controlled binding. The high affinity interaction provides strong on-target binding, while the reversible nature of chemical interactions allows for feedback control - non-specific bindings can be washed away, and specific bindings are retained. This feedback approach helps distinguish true targets from off-target interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high flexibility in ligand targeting, increasing on-target delivery and reducing off-target effects, providing a broader therapeutic window for EVs in diagnostic and therapeutic applications.
Implementation Method 1
at least one of the extracellular domains of the said engineered transmembrane protein comprises a segment having a high affinity for a chemical derivative (2) not expressed by the said Eukaryotic cell
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
An engineered Eukaryotic cell expressing a transmembrane protein having the potential to be sorted into an extracellular vesicle from the said Eukaryotic cell, wherein the extracellular domain of the said transmembrane protein comprises a segment having a high affinity for a chemical derivative not expressed by the said Eukaryotic cell, or a derivatization domain, a method to identify targeting ligands for extracellular vesicles and the extracellular vesicles decorated with such ligand.